Vimarsana
Biggest News Aggregation in the World

Page 3 - Discovery Engine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Discovery Engine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Discovery Engine Today - Breaking & Trending Today

DIY Guide: Creating a Stylish Girl's Bed Headboard on Pinterest - Vimarsana News

DIY Guide: Creating a Stylish Girl's Bed Headboard on Pinterest

Have you ever seen your daughter’s bedroom and wondered what was missing? Perhaps it’s the absence of a charming headboard that would transform her space into a dreamy haven. It would be very exciting for her if she found a bed that fit snugly for a princess when she woke up. How did you make […]

Transcript : Arvinas, Inc. - Special Call -October 22, 2023 at 09:00 am EDT - Vimarsana News

Transcript : Arvinas, Inc. - Special Call -October 22, 2023 at 09:00 am EDT

Presentation Operator MessageOperator Hello, and welcome to the ESMO Data Presentation. [Operator Instructions] Please be advised that today's conference is being recorded.It is now my pleasure to...

Related Topics:
Arvinas IncDiscovery Engine
Potential of Arvinas' PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide ... | Region - Vimarsana News

Potential of Arvinas' PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide ... | Region

– Data presented at the European Society for Medical Oncology from the Phase 1/2 trial with bavdegalutamide showed 11.1 months radiographic progression free survival in mCRPC patients with tumors harboring

Potential of Arvinas' PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC -October 22, 2023 at 07:01 am EDT - Vimarsana News

Potential of Arvinas' PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC -October 22, 2023 at 07:01 am EDT

– Data presented at the European Society for Medical Oncology from the Phase 1/2 trial with bavdegalutamide showed 11.1 months radiographic progression free survival in mCRPC patients with tumors...

Arvinas Announces Upcoming Bavdegalutamide Poster - Vimarsana News

Arvinas Announces Upcoming Bavdegalutamide Poster

NEW HAVEN, Conn., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...